acute lymphocytic leukemia
Conditions
Interventions
Philadelphia positive acute lymphoblastic leukemia subgroup:Targeted therapy is PD-1 antibody combined with conventional chemotherapy
Philadelphia-like (Ph-like) acute lymphoblastic leukemia :conventional chemotherapy
CD20 positive (> 20%) B precursor cells -ALL subgroup:conventional chemotherapy
Non-specific type B progenitor cell acute lymphoblastic leukemia subgroup:conventional chemotherapy
T-cell acute lymphoblastic leukemia:conventional chemotherapy
Mixed series acute leukemia MPAL subgroup:conventional chemotherapy
Sponsors
Department of Hematology, Nanfang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
15 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Age =14 years old, =55 years old, gender is not limited; 2. Newly diagnosed acute lymphoblastic leukemia, untreated; 3. At the same time meet the reserve function conditions of important organs: cardiac ultrasound LVEF=50%; TBIL = 1.5ULN; AST/ALT =2.5ULN; Serum creatinine level =1.5ULN; 4. The researchers assessed that the expected survival time was greater than 3 months; 5. Voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1.Burkitt lymphoma/leukemia; 2. Acute undifferentiated leukemia; 3. Pregnant women; 4. Severe uncontrolled active infection; 5. Patients with a history of pancreatitis; 6. Patients with severe diabetes who need to use insulin to control blood sugar; 7. Patients with a history of active gastrointestinal bleeding within the last 6 months; 8. History of arterial/venous thrombosis within the last 6 months; 9. In addition to leukemia, there are other tumors; 10. Patients with a history of allergy to any drug in the PDT-ALL-2016 regimen; 11. Other situations deemed unsuitable for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| event-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| minimal residual disease negative conversion rate;AEs; | — |
Countries
China
Contacts
Public ContactLiu Qifa
Nanfang Hospital, Southern Medical University
Outcome results
None listed